Comparison of HIV-1 and EIAV-based lentiviral vectors in corneal transduction

被引:40
|
作者
Beutelspacher, SC
Ardjomand, N
Tan, PH
Patton, GS
Larkin, DFP
George, AJT
McClure, MO
机构
[1] Univ London Imperial Coll Sci & Technol, Fac Med, Wright Fleming Inst Imperial Coll London, Div Med,Dept GU Med,Jefferiss Res Trust Labs, London W2 1PG, England
[2] Univ London Imperial Coll Sci & Technol, Hamanoumachi Hosp, Fac Med, Div Med,Dept Immunol, London W12 0NN, England
[3] Moorfields Eye Hosp, London EC1V 2PD, England
关键词
cornea; EIAV; gene therapy; HIV-1; inducible promoter;
D O I
10.1016/j.exer.2004.12.005
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
In this study we compare the ability of self-inactivating Hum an Immunodeficiency Virus 1 (HIV-1) and Equine Infectious Anaemia Virus (EIAV)-based vectors to mediate gene transfer to rabbit and human corneas and to a murine corneal endothelial cell line. Both vectors were pseudotyped with vesicular stomatitis virus-G (VSV-G) envelope and contained marker transgenes under the control of an internal CMV promoter. For specificity of action, the heterologous promoter in the EIAV-vector was exchanged for an inducible E-Selectin promoter, previously shown to regulate gene-expression in a plasmid system. We show that EIAV is more efficient than HIV in transducing human and rabbit corneal endothelial cells. Rabbit corneal endothelial cells are transduced in higher quantity than human corneal endothelial cells. In the inducible system, however, we detected impairment between the vector and its internal E-Selectin promoter. Instead of controlled transgene expression or silencing of promoter activity, the U3-modified long-terminal-repeats (LTR) impaired the conditional activity of the E-Selectin promoter. Significant transgene expression was seen without stimulation of the inducible promoter. We show efficient transduction by lentiviruses of a corneal endothelial cell line and of full thickness corneas from different species, confirming that those vectors would be appropriate tools for gene therapy of selected corneal diseases. However, the modification within the U3-LTR did not adequately allow regulated transgene expression. These findings have important implications for vector design for diagnostic or therapeutic opportunities. (c) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:787 / 794
页数:8
相关论文
共 50 条
  • [1] New methods to titrate EIAV-based lentiviral vectors
    Martin-Rendon, E
    White, LJ
    Olsen, A
    Mitrophanous, KA
    Mazarakis, ND
    [J]. MOLECULAR THERAPY, 2002, 5 (05) : 566 - 570
  • [2] EIAV-based vectors for the treatment of haemophilia A
    Radcliffe, PA
    Wilkes, FJ
    Beard, GL
    Kingsman, SM
    Mitrophanous, KA
    [J]. MOLECULAR THERAPY, 2004, 9 : S64 - S64
  • [3] The integration profile of EIAV-based vectors
    Hacker, Caroline V.
    Vink, Conrad A.
    Wardell, Theresa W.
    Lee, Sheena
    Treasure, Peter
    Kingsman, Susan M.
    Mitrophanous, Kyriacos A.
    Miskin, James E.
    [J]. MOLECULAR THERAPY, 2006, 14 (04) : 536 - 545
  • [4] Comparison of HIV- and EIAV-based vectors on their efficiency in transducing murine and human hematopoietic repopulating cells
    Siapati, EK
    Bigger, BW
    Miskin, J
    Chipchase, D
    Parsley, KL
    Mitrophanous, K
    Themis, M
    Thrasher, AJ
    Bonnet, D
    [J]. MOLECULAR THERAPY, 2005, 12 (03) : 537 - 546
  • [5] Reversal of hypothalamic diabetes insipidus using EIAV-based regulatable lentiviral vectors expressing arginine vasopressin
    Radcliffe, BP
    Cosgrave, S
    Mitrophanous, K
    Mazarakis, N
    Uney, JB
    [J]. JOURNAL OF GENE MEDICINE, 2004, 6 (09): : S35 - S36
  • [6] Non-primate EIAV-based lentiviral vectors as gene delivery system for motor neuron diseases
    Azzouz, M
    Mazarakis, N
    [J]. CURRENT GENE THERAPY, 2004, 4 (03) : 277 - 286
  • [7] Reversal of hypothalamic diabetes insipidus using EIAV-based regulatable lentiviral vectors expressing arginine vasopressin
    Bienemann, A
    Radcliffe, P
    Mitrophanous, K
    Glover, C
    Mazarakis, N
    Uney, J
    [J]. MOLECULAR THERAPY, 2004, 9 : S241 - S241
  • [8] Lentiviral vectors based on HIV-1, HIV-2 and SIV
    Lever, AML
    [J]. CANCER GENE THERAPY, 2004, 11 (12) : 846 - 846
  • [9] Both HIV- and EIAV-based lentiviral vectors mediate gene delivery to pancreatic cancer cells and human pancreatic primary patient xenografts
    G Saraga
    A Mafficini
    P Ghaneh
    C Sorio
    E Costello
    [J]. Cancer Gene Therapy, 2007, 14 : 781 - 790
  • [10] Both HIV- and EIAV-based lentiviral vectors mediate gene delivery to pancreatic cancer cells and human pancreatic primary patient xenografts
    Saraga, G.
    Mafficini, A.
    Ghaneh, P.
    Sorio, C.
    Costello, E.
    [J]. CANCER GENE THERAPY, 2007, 14 (09) : 781 - 790